Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLA-A2-restricted peptides + CpG 7909
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptides, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
A cancer immunotherapy approach combining HLA-A2-restricted tumor antigen peptides with CpG 7909, a synthetic oligodeoxynucleotide that acts as a Toll-like receptor 9 (TLR9) agonist. This combination aims to enhance both innate and adaptive immune responses against cancer cells by stimulating plasmacytoid dendritic cells and B cells while generating stronger antigen-specific CD8+ T cell responses.
- Other names
- CpG 7909 + HLA-A2-restricted peptides
02
Targets
TLR9 (Toll-like receptor 9)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on HLA-A2-restricted peptides + CpG 7909.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLA-A2-restricted peptides + CpG 7909.